Literature DB >> 27849134

Developing and characterization of single chain variable fragment (scFv) antibody against frizzled 7 (Fzd7) receptor.

Hamid Nickho1,2,3, Vahid Younesi4,5, Leili Aghebati-Maleki1,2,3, Morteza Motallebnezhad1,2,3, Jafar Majidi Zolbanin1,2,3, Aliakbar Movassagh Pour1,2,3, Mehdi Yousefi2,3.   

Abstract

ABSTACT Wnt/β-catenin signaling pathway through Frizzled receptors has been shown to play a key role in both normal development and tumorigenesis. Overexpression of Wnt pathway genes, such as Fzd7 in several malignancies is well-documented. Therefore, targeting of Fzd7 and its ligand inhibits cancer cells proliferation metastasis. In the present study we isolated single chain variable fragments (scFvs) against Fzd7 receptor using phage display method. Semi-synthetic human naive antibody libraries (Tomlinson I + J) was employed in panning procedure to isolate specific scFv against specific peptide from extracellular domain of Fzd7 receptor. The reactivity and growth inhibition effects of the selected antibodies was evaluated using enzyme-linked immunosorbent assay (ELISA), MTT and annexin V assays, respectively. Seven scFvs reactive to Fzd7 were selected following 4 rounds of panning. The results showed that the selected scFvs inhibits cell growth through apoptosis cell death in a triple negative breast cancer cells, MDA-MB-231. Given that Fzd7 and Wnt pathway plays a critical role in tumor progression, selected blocking scFvs represent significant potential for immunotherapy of breast cancer cells.

Entities:  

Keywords:  Fzd7; Wnt; breast cancer; phage display; scFv

Mesh:

Substances:

Year:  2016        PMID: 27849134      PMCID: PMC5639855          DOI: 10.1080/21655979.2016.1255383

Source DB:  PubMed          Journal:  Bioengineered        ISSN: 2165-5979            Impact factor:   3.269


  47 in total

1.  Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.

Authors:  Brian D Lehmann; Joshua A Bauer; Xi Chen; Melinda E Sanders; A Bapsi Chakravarthy; Yu Shyr; Jennifer A Pietenpol
Journal:  J Clin Invest       Date:  2011-07       Impact factor: 14.808

2.  Oncogenic role of the frizzled-7/beta-catenin pathway in hepatocellular carcinoma.

Authors:  Philippe Merle; Miran Kim; Marc Herrmann; Anand Gupte; Lydie Lefrançois; Sophia Califano; Christian Trépo; Shinji Tanaka; Ludmila Vitvitski; Suzanne de la Monte; Jack R Wands
Journal:  J Hepatol       Date:  2005-06-21       Impact factor: 25.083

3.  FZD7 has a critical role in cell proliferation in triple negative breast cancer.

Authors:  L Yang; X Wu; Y Wang; K Zhang; J Wu; Y-C Yuan; X Deng; L Chen; C C H Kim; S Lau; G Somlo; Y Yen
Journal:  Oncogene       Date:  2011-05-02       Impact factor: 9.867

Review 4.  The complex roles of Wnt antagonists in RCC.

Authors:  Sharanjot Saini; Shahana Majid; Rajvir Dahiya
Journal:  Nat Rev Urol       Date:  2011-10-25       Impact factor: 14.432

5.  Induction of anti-proliferative and apoptotic effects by anti-IL-25 receptor single chain antibodies in breast cancer cells.

Authors:  Vahid Younesi; Foroogh Nejatollahi
Journal:  Int Immunopharmacol       Date:  2014-12       Impact factor: 4.932

Review 6.  The Wnt/β-catenin signaling pathway: a potential therapeutic target in the treatment of triple negative breast cancer.

Authors:  Taj D King; Mark J Suto; Yonghe Li
Journal:  J Cell Biochem       Date:  2012-01       Impact factor: 4.429

7.  Soy isoflavone genistein upregulates epithelial adhesion molecule E-cadherin expression and attenuates beta-catenin signaling in mammary epithelial cells.

Authors:  Ying Su; Rosalia C M Simmen
Journal:  Carcinogenesis       Date:  2008-12-10       Impact factor: 4.944

8.  Chronological expression of Wnt target genes Ccnd1, Myc, Cdkn1a, Tfrc, Plf1 and Ramp3.

Authors:  Sonja Röhrs; Nadine Kutzner; Annica Vlad; Thomas Grunwald; Slava Ziegler; Oliver Müller
Journal:  Cell Biol Int       Date:  2009-04       Impact factor: 3.612

Review 9.  WNT and beta-catenin signalling: diseases and therapies.

Authors:  Randall T Moon; Aimee D Kohn; Giancarlo V De Ferrari; Ajamete Kaykas
Journal:  Nat Rev Genet       Date:  2004-09       Impact factor: 53.242

10.  Targeting the WNT/beta-catenin/TCF/LEF1 axis in solid and haematological cancers: Multiplicity of therapeutic options.

Authors:  Iris Gehrke; Rajesh Kumar Gandhirajan; Karl-Anton Kreuzer
Journal:  Eur J Cancer       Date:  2009-09-02       Impact factor: 9.162

View more
  5 in total

1.  Dendritic cells in tumor microenvironment promoted the neuropathic pain via paracrine inflammatory and growth factors.

Authors:  Zhun Wang; Kai Song; Wenxin Zhao; Zhongmin Zhao
Journal:  Bioengineered       Date:  2020-12       Impact factor: 3.269

2.  Discovery of novel frizzled-7 inhibitors by targeting the receptor's transmembrane domain.

Authors:  Wei Zhang; Wenyan Lu; Subramaniam Ananthan; Mark J Suto; Yonghe Li
Journal:  Oncotarget       Date:  2017-09-06

Review 3.  Frizzled Receptors as Potential Therapeutic Targets in Human Cancers.

Authors:  Chui-Mian Zeng; Zhe Chen; Li Fu
Journal:  Int J Mol Sci       Date:  2018-05-22       Impact factor: 5.923

4.  LRP5 regulates the expression of STK40, a new potential target in triple-negative breast cancers.

Authors:  Sylvie Maubant; Tania Tahtouh; Amélie Brisson; Virginie Maire; Fariba Némati; Bruno Tesson; Mengliang Ye; Guillem Rigaill; Maïté Noizet; Aurélie Dumont; David Gentien; Bérengère Marty-Prouvost; Leanne de Koning; Sardar Faisal Mahmood; Didier Decaudin; Francisco Cruzalegui; Gordon C Tucker; Sergio Roman-Roman; Thierry Dubois
Journal:  Oncotarget       Date:  2018-04-27

Review 5.  Single-Chain Fragment Variable: Recent Progress in Cancer Diagnosis and Therapy.

Authors:  Paola Muñoz-López; Rosa María Ribas-Aparicio; Elayne Irene Becerra-Báez; Karla Fraga-Pérez; Luis Fernando Flores-Martínez; Armando Alfredo Mateos-Chávez; Rosendo Luria-Pérez
Journal:  Cancers (Basel)       Date:  2022-08-30       Impact factor: 6.575

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.